Suggested remit: To evaluate the benefits and costs of OTL-200 within its marketing authorisation for treating metachromatic leukodystrophy for national commissioning by NHS England.
Status Proposed
Process HST
ID number 1666

Provisional Schedule

Scoping workshop (London) 27 January 2020 (14:00)

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
14 November 2019 - 12 December 2019 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance